Arrowhead Wins UK Marketing Authorisation for REDEMPLO
The MHRA approved REDEMPLO (plozasiran) for adults with familial chylomicronaemia syndrome who have not responded adequately to diet and conventional triglyceride-lowering therapies. The treatment is also available on the NHS in England and Wales following positive guidance.
Arrowhead Pharmaceuticals announced that the MHRA has granted marketing authorisation for REDEMPLO (plozasiran) for the treatment of adults with Familial Chylomicronaemia Syndrome (FCS) in the United Kingdom. This approval allows for the drug's use in patients who have had an inadequate response to diet and conventional triglyceride-lowering therapies. The company noted that the treatment is also available on the NHS in England and Wales following positive guidance. REDEMPLO is designed to reduce extremely high levels of triglycerides in the bloodstream by silencing the genes responsible for the condition.
This regulatory milestone marks a significant step in the company's commercial expansion for its RNAi therapeutic portfolio.